Literature DB >> 33766512

In-Depth Analysis of the Hidradenitis Suppurativa Serum Proteome Identifies Distinct Inflammatory Subtypes.

Kristina Navrazhina1, Sandra Garcet2, Juana Gonzalez2, David Grand2, John W Frew2, James G Krueger3.   

Abstract

Hidradenitis suppurativa is a chronic inflammatory dermatosis with presentations ranging from painful nodules and abscesses to draining tunnels. Using an unbiased proteomics approach, we assessed cardiovascular-, cardiometabolic-, and inflammation-related biomarkers in the serum of patients with moderate-to-severe hidradenitis suppurativa. The serum of patients with hidradenitis suppurativa clustered separately from that of healthy controls and had an upregulation of neutrophil-related markers (Cathepsin D, IL-17A, CXCL1). Patients with histologically diagnosed dermal tunnels had higher serum lipocalin-2 levels compared with those without tunnels. Consistent with this, patients with tunnels had a more neutrophilic-rich serum signature, marked by Cathepsin D, IL-17A, and IL-17D alterations. There was a significant serum‒skin correlation between proteins in the serum and the corresponding mRNA expression in skin biopsies, with healthy-appearing perilesional skin demonstrating a significant correlation with neutrophil-related proteins in the serum. CSF3 mRNA levels in lesional skin significantly correlated with neutrophil-related proteins in the serum, suggesting that CFS3 in the skin may be a driver of neutrophilic inflammation. Clinical significantly correlated with the levels of lipocalin-2 and IL-17A in the serum. Using an unbiased, large-scale proteomic approach, we demonstrate that hidradenitis suppurativa is a systemic neutrophilic dermatosis, with a specific molecular signature associated with the presence of dermal tunnels.
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33766512      PMCID: PMC8384651          DOI: 10.1016/j.jid.2021.02.742

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   7.590


  74 in total

1.  Interleukin 17C is elevated in lesional tissue of hidradenitis suppurativa.

Authors:  K Navrazhina; J W Frew; J G Krueger
Journal:  Br J Dermatol       Date:  2019-12-03       Impact factor: 9.302

Review 2.  Hidradenitis suppurativa: Epidemiology and scope of the problem.

Authors:  Gregor B E Jemec; Alexa B Kimball
Journal:  J Am Acad Dermatol       Date:  2015-11       Impact factor: 11.527

3.  G-CSF is an essential regulator of neutrophil trafficking from the bone marrow to the blood.

Authors:  Craig L Semerad; Fulu Liu; Alyssa D Gregory; Katherine Stumpf; Daniel C Link
Journal:  Immunity       Date:  2002-10       Impact factor: 31.745

4.  Lipocalin-2 is expressed by activated granulocytes and keratinocytes in affected skin and reflects disease activity in acne inversa/hidradenitis suppurativa.

Authors:  K Wolk; J Wenzel; A Tsaousi; E Witte-Händel; N Babel; C Zelenak; H-D Volk; W Sterry; S Schneider-Burrus; R Sabat
Journal:  Br J Dermatol       Date:  2017-09-19       Impact factor: 9.302

5.  The blood proteomic signature of early-onset pediatric atopic dermatitis shows systemic inflammation and is distinct from adult long-standing disease.

Authors:  Patrick M Brunner; Helen He; Ana B Pavel; Tali Czarnowicki; Rachel Lefferdink; Taylor Erickson; Talia Canter; Neha Puar; Stephanie M Rangel; Kunal Malik; Yeriel Estrada; James G Krueger; Emma Guttman-Yassky; Amy S Paller
Journal:  J Am Acad Dermatol       Date:  2019-04-19       Impact factor: 11.527

6.  Crucial role of neutrophils in the development of mechanical inflammatory hypernociception.

Authors:  Thiago M Cunha; Waldiceu A Verri; Ieda R Schivo; Marcelo H Napimoga; Carlos A Parada; Stephen Poole; Mauro M Teixeira; Sergio H Ferreira; Fernando Q Cunha
Journal:  J Leukoc Biol       Date:  2008-01-18       Impact factor: 4.962

7.  IL-17 stimulates granulopoiesis in mice: use of an alternate, novel gene therapy-derived method for in vivo evaluation of cytokines.

Authors:  P Schwarzenberger; V La Russa; A Miller; P Ye; W Huang; A Zieske; S Nelson; G J Bagby; D Stoltz; R L Mynatt; M Spriggs; J K Kolls
Journal:  J Immunol       Date:  1998-12-01       Impact factor: 5.422

8.  Depression is a frequent co-morbidity in patients with acne inversa.

Authors:  Agata Kurek; Eva Milena Johanne Peters; Robert Sabat; Wolfram Sterry; Sylke Schneider-Burrus
Journal:  J Dtsch Dermatol Ges       Date:  2013-04-09       Impact factor: 5.584

9.  Lipocalin-2 counteracts metabolic dysregulation in obesity and diabetes.

Authors:  Ioanna Mosialou; Steven Shikhel; Na Luo; Peristera Ioanna Petropoulou; Konstantinos Panitsas; Brygida Bisikirska; Nyanza J Rothman; Roxane Tenta; Bertrand Cariou; Matthieu Wargny; Elisabeth Sornay-Rendu; Thomas Nickolas; Mishaela Rubin; Cyrille B Confavreux; Stavroula Kousteni
Journal:  J Exp Med       Date:  2020-10-05       Impact factor: 14.307

10.  The Reactome pathway knowledgebase.

Authors:  David Croft; Antonio Fabregat Mundo; Robin Haw; Marija Milacic; Joel Weiser; Guanming Wu; Michael Caudy; Phani Garapati; Marc Gillespie; Maulik R Kamdar; Bijay Jassal; Steven Jupe; Lisa Matthews; Bruce May; Stanislav Palatnik; Karen Rothfels; Veronica Shamovsky; Heeyeon Song; Mark Williams; Ewan Birney; Henning Hermjakob; Lincoln Stein; Peter D'Eustachio
Journal:  Nucleic Acids Res       Date:  2013-11-15       Impact factor: 16.971

View more
  8 in total

1.  Interleukin-17RA blockade by brodalumab decreases inflammatory pathways in hidradenitis suppurativa skin and serum.

Authors:  Kristina Navrazhina; John W Frew; David Grand; Samuel C Williams; Hong Hur; Juana Gonzalez; Sandra Garcet; James G Krueger
Journal:  Br J Dermatol       Date:  2022-06-02       Impact factor: 11.113

2.  Autoantibodies Present in Hidradenitis Suppurativa Correlate with Disease Severity and Promote the Release of Proinflammatory Cytokines in Macrophages.

Authors:  Carmelo Carmona-Rivera; Liam J O'Neil; Eduardo Patino-Martinez; William D Shipman; Chengsong Zhu; Quan-Zhen Li; Michelle L Kerns; Leandra A Barnes; Julie A Caffrey; Sewon Kang; Mariana J Kaplan; Ginette A Okoye; Angel S Byrd
Journal:  J Invest Dermatol       Date:  2021-10-01       Impact factor: 8.551

3.  Identification of Biomarkers and Critical Evaluation of Biomarker Validation in Hidradenitis Suppurativa: A Systematic Review.

Authors:  Samuel Der Sarkissian; Schapoor Hessam; Joslyn S Kirby; Michelle A Lowes; Dillon Mintoff; Haley B Naik; Hans Christian Ring; Nisha Suyien Chandran; John W Frew
Journal:  JAMA Dermatol       Date:  2022-03-01       Impact factor: 11.816

Review 4.  Lipocalin 2 Participates in the Epidermal Differentiation and Inflammatory Processes of Psoriasis.

Authors:  Kaixuan Ren; Yumin Xia
Journal:  J Inflamm Res       Date:  2022-03-31

Review 5.  Innate immunity and microbial dysbiosis in hidradenitis suppurativa - vicious cycle of chronic inflammation.

Authors:  Divya Chopra; Rachel A Arens; Watcharee Amornpairoj; Michelle A Lowes; Marjana Tomic-Canic; Natasa Strbo; Hadar Lev-Tov; Irena Pastar
Journal:  Front Immunol       Date:  2022-07-28       Impact factor: 8.786

6.  Recent advances in hidradenitis suppurativa: Role of race, genetics, and immunology.

Authors:  Gautham Vellaichamy; Anya T Amin; Peter Dimitrion; Zaakir Hamzavi; Li Zhou; Indra Adrianto; Qing-Sheng Mi
Journal:  Front Genet       Date:  2022-08-26       Impact factor: 4.772

7.  The inflammatory proteome of hidradenitis suppurativa skin is more expansive than that of psoriasis vulgaris.

Authors:  Kristina Navrazhina; Sandra Garcet; John W Frew; Xiuzhong Zheng; Israel Coats; Emma Guttman-Yassky; James G Krueger
Journal:  J Am Acad Dermatol       Date:  2021-07-30       Impact factor: 11.527

8.  Primary alterations during the development of hidradenitis suppurativa.

Authors:  Z Dajnoki; O Somogyi; B Medgyesi; A Jenei; L Szabó; K Gáspár; Z Hendrik; P Gergely; D Imre; S Póliska; D Törőcsik; C C Zouboulis; E P Prens; A Kapitány; A Szegedi
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-11-26       Impact factor: 9.228

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.